ORLANDO, Fla., April 10 /PRNewswire-FirstCall/ -- Telzuit Medical Technologies, Inc. (the “Company” or “Telzuit”) announced today that it has signed an agreement with Cingular Wireless, a joint venture between AT&T Inc. and BellSouth Corporation , for the cellular transfer of data sent by Telzuit’s Bio-Patch PDA to the Telzuit data center. The soon-to-be-launched Bio-Patch will collect a 12-Lead ECG from the patient and transfer it to the patient’s Bio-Patch PDA. From there the proprietary PDA will then utilize Cingular’s national footprint to wirelessly transport the patient’s cardiac data to the Telzuit data center in Orlando, Florida. In addition, Telzuit signed an agreement with Asurion Managed Wireless for the staging of Bio-Patch PDA hardware, equipment protection and all related support. Terms of the agreements were not disclosed.
(Photo: http://www.newscom.com/cgi-bin/prnh/20060410/NYM028 )
Warren Stowell, CEO of Telzuit, commented, “These agreements provide our Bio-Patch platform with wireless monitoring on a national level and mark an important step in the nationwide implementation of the Bio-Patch Wireless Holter Monitor System. Mobile access is a critical function of our Bio-Patch System, and partnering with a wireless company of Cingular’s caliber gives us great confidence that our patients and physicians will receive nationwide wireless service of the highest quality.”
About Telzuit Medical Technologies, Inc.
Telzuit Medical Technologies, Inc. is dedicated to providing advanced mobile medicine for people worldwide. The company is in the final stages of launching its first product, the FDA-approved Bio-Patch Wireless Heart Monitor. The Bio-Patch is a full 12-lead, completely wireless Holter monitor, which is new to the marketplace. In conjunction with its strategic partners, Telzuit is also building its own dedicated intranet platform to handle several of the products it will be releasing, including the Bio-Patch. Telzuit is based in Orlando, Florida. For more information Telzuit, its business model and its products, please visit the company’s website: http://www.telzuit.com .
Forward Looking Statement: Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties, including the effect of changing economic conditions, competition within the health products industry, customer acceptance of products, and other risks and uncertainties. Such forward-looking statements are not guarantees of performance, and Telzuit results could differ materially from those contained in such statements. These forward-looking statements speak only as of the date of this release, and Telzuit undertake no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this release.
Contact: Telzuit Medical Technologies, Inc. James Tolan Co-Founder, Telzuit Medical Technologies, Inc. 407-354-1222 Brainerd Communicators, Inc. Jennifer Gery (media) Todd St.Onge (investors) 212-986-6667
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20060410/NYM028AP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comTelzuit Medical Technologies, Inc.
CONTACT: James Tolan, Co-Founder of Telzuit Medical Technologies, Inc.,+1-407-354-1222; Jennifer Gery (media) or Todd St.Onge (investors), both ofBrainerd Communicators, Inc., +1-212-986-6667, for Telzuit MedicalTechnologies, Inc.
Web site: http://www.telzuit.com/
